Buy & Sell ProShares UltraPro S&P500 (UPRO) – ProShares UltraPro S&P500 Price Today
Aura AI Summary
Key Stats
- -Market Cap
- Leveraged / InverseSector
- -22.57%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 10 daysTypical Hold Time
Over the past 52 weeks, ProShares UltraPro S&P500 has traded between a low of $79.78 and a high of $149.11, highlighting its annual price range. Over the past three months, ProShares UltraPro S&P500 has recorded a drawdown of -22.57%, reflecting recent price volatility. On average, investors hold ProShares UltraPro S&P500 for approximately 10 days, indicating typical investor behavior on the platform.
About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Most Recent News
ExxonMobil warns oil prices could spike to $160/barrel amid low inventories and geopolitical tensions.
ExxonMobil's Senior Vice President Neil Chapman warned that crude oil prices could surge to $150-$160 per barrel soon due to critically low inventory levels, despite recent price drops linked to U.S.-Iran peace talks. The company highlighted that str...

XRP shows signs of bottoming as smart money accumulates and ETFs hit best month of 2026.
XRP has shown signs of bottoming after a five-month consolidation, with smart money investors increasing accumulation. XRP ETFs recorded their best month in 2026, adding $131 million in inflows in May, contrasting with declines in Bitcoin and Ethereu...

Whitehawk reveals SEZ6 as a promising target for new cancer drug HWK-206, advancing to clinical trials in 2026.
Whitehawk Therapeutics announced data showing SEZ6 protein is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors, exceeding other known targets. This supports their development of HWK-206, a next-generation antibody dru...
